Dr. Moyer, VP at Epizyme to speak at 2nd Epigenetics Drug Discovery Conference May 30-31 2012 Boston
Mikel Moyer, Vice President of Molecular Discovery at Epizyme will give a presentation on "Protein Methyl Transferases: a Novel Target Class for Molecularly Targeted Therapy against Genetically Defined Cancers" at the 2nd Epigenetics in Drug Discovery Conference taking place on May 30-31, 2012 in Boston, MA.
- (1888PressRelease) April 11, 2012 - Post-translational modifications on histones play important regulatory roles in the control of gene transcription. The modifications include methylation, acetylation, phosphorylation, ubiqutinylation and sumoylation. Recent evidence shows that the enzymes that regulate methylation of lysine and arginine residues in histones, including both methyltransferases and demethylases, are misregulated in a variety of cancers. There are approximately 100 related histone methyltransferase enzymes and these enzymes are attractive targets for drug discovery efforts, due to their disease association and druggability.
Dr. Moyer will present on Epizyme's biased library of protein methyltransferase inhibitors, which is proving to be an effective and efficient means of identifying potent, selective inhibitors for a number of these enzymes leading to attractive chemical starting points for drug discovery programs.
Dr. Moyer's responsibilities at Epizyme include medicinal chemistry, biochemistry and cell-based assays, protein and structural sciences, and DMPK. Mike joined Epizyme in March, 2010, from the Broad Institute, where he was Director of Medicinal Chemistry in the Stanley Center for Psychiatric Research. During his three years at the Broad Institute, Mike was responsible for establishing a medicinal chemistry research group aimed at discovering novel therapeutics for the treatment of schizophrenia and bipolar disorder. Prior to the Broad, Mike held a variety of leadership positions during 18 years at Pfizer, where he led medicinal chemistry groups that moved 25 compounds from discovery into development across five therapeutic areas - including oncology. The most advanced compound from these efforts has reached the market (Tarceva™) with a second compound undergoing Phase III testing (tofacitinib). Prior to Pfizer, Mike was a medicinal chemist in the immunoscience area at Abbott Laboratories.
GTC's 2nd Epigenetics in Drug Discovery conference is the only epigenetics conference that brings together a balanced mix of leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, technologies and diagnostics for epigenetics drug discovery. Some key discussions around epigenetics drug discovery at the conference include:
- The role of epigenetics in human diseases such as cancer, leukaemia, neurodegenerative conditions, neuropsychiatric disorders, inflammation, etc
- Cutting edge research from GlaxoSmithKline, Epizyme, Genentech, Constellation, Cellzome, RaNA Therapeutics, Pfizer, Harvard, Massachusetts Institute of Technology, etc.
The conference is part of the Omics Evolution Summit, which includes 6 co-located conferences. Register for the entire summit and have access to the all of the following conferences:
2nd Genomic & Proteomic Drug Discovery Conference
3rd RNAi Research and Development Conference
7th Protein Kinases in Drug Discovery Conference
2nd Next Generation Sequencing Conference
Genome-wide Partnering and Deal Making Conference
Sign up for the pre-summit workshop on Clinical Sequencing on May 29th. This interactive workshop is dedicated to discussing emerging technologies, current and future trends of clinical sequencing, and the implementation of next generation sequencing in a CLIA environment.
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam